Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Removal of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Conditions:   Stage IV Non-small Cell Lung Cancer;   Stage IV Melanoma;   Triple Negative Breast Cancer;   Renal Cell Carcinoma Stage IV Intervention:   Combination Product: ImmunicomAIAC Sponsor:   Prof. Gal Markel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials